{"id":"ffp-and-cryoprecipitate","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Fluid overload"},{"rate":null,"effect":"Infection transmission (rare with modern screening)"},{"rate":null,"effect":"Thrombosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FFP is a plasma product containing all vitamin K-dependent factors, fibrinogen, and other coagulation proteins, used to correct multiple factor deficiencies. Cryoprecipitate is a concentrated source of fibrinogen, von Willebrand factor, factor VIII, fibronectin, and factor XIII, used primarily to restore fibrinogen levels in bleeding or coagulopathic states. Together, they address acute coagulation defects through factor replacement.","oneSentence":"FFP (Fresh Frozen Plasma) and Cryoprecipitate are blood products that replace deficient clotting factors and fibrinogen to restore hemostatic function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:35.127Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bleeding due to coagulation factor deficiency"},{"name":"Fibrinogen replacement in hypofibrinogenemia"},{"name":"Disseminated intravascular coagulation (DIC)"},{"name":"Massive transfusion protocols"},{"name":"Perioperative hemostasis management"}]},"trialDetails":[{"nctId":"NCT07437755","phase":"NA","title":"Thrombelastometry-guided Blood Component Administration Versus Standard of Care in Patients With Decompensated Liver Cirrhosis Undergoing Invasive Procedures","status":"RECRUITING","sponsor":"Grigore T. Popa University of Medicine and Pharmacy","startDate":"2025-06-01","conditions":"Liver Cirrhosis With Acute Decompensation","enrollment":116},{"nctId":"NCT03444324","phase":"PHASE3","title":"Adjusted Fibrinogen Replacement Strategy","status":"COMPLETED","sponsor":"Biotest","startDate":"2018-04-03","conditions":"Bleeding Disorder, Hypofibrinogenemia; Acquired","enrollment":222},{"nctId":"NCT06153082","phase":"NA","title":"Rotational Thromboelastometry [ROTEM] vs Thromboelastography [TEG] Guided Blood Component Use in Patients With Cirrhosis of Liver With Non-variceal Bleeding.","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-12-16","conditions":"Liver Cirrhosis","enrollment":80},{"nctId":"NCT03045068","phase":"PHASE4","title":"Platelet Transfusion During Neonatal Open Heart Surgery","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2017-04-11","conditions":"Cardiac Disease, Cardiac Surgery, Cardiopulmonary Bypass","enrollment":46},{"nctId":"NCT04460222","phase":"NA","title":"Rotational Thromboelastometry Guided Blood Component Use in Children With Cirrhosis Undergoing Invasive Procedures: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2020-11-16","conditions":"Cirrhosis, Liver","enrollment":60},{"nctId":"NCT03784794","phase":"NA","title":"Patient Blood Management for Massive Obstetric Hemorrhage","status":"COMPLETED","sponsor":"Angel Augusto Perez Calatayud","startDate":"2018-11-01","conditions":"Post Partum Hemorrhage, Fibrinogenolysis; Hemorrhage, Fibrinogen; Deficiency, Acquired","enrollment":100},{"nctId":"NCT00945542","phase":"PHASE1, PHASE2","title":"The Trauma- Formula-Driven Versus Lab-Guided Study (TRFL Study)","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2009-07","conditions":"Hemorrhagic Shock, Trauma Coagulopathy","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":284,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FFP"],"phase":"marketed","status":"active","brandName":"FFP and Cryoprecipitate","genericName":"FFP and Cryoprecipitate","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Biologic","firstApprovalDate":"","aiSummary":"FFP (Fresh Frozen Plasma) and Cryoprecipitate are blood products that replace deficient clotting factors and fibrinogen to restore hemostatic function. Used for Acute bleeding due to coagulation factor deficiency, Fibrinogen replacement in hypofibrinogenemia, Disseminated intravascular coagulation (DIC).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}